Gamida Cell
Gamida Cell FY 2023: revenue $1.8M; diluted EPS $0.57
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-24-026229
- Document
- 10-K
- Exhibit 4.1
- Description of securities
- Exhibit 10.6
- 2017 share incentive plan, as amended
Key figures from this report
These are the numbers Gamida Cell reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.8MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$63.0MAgainst −$79.4M in FY 202210-K income statement, on EDGAR
- Diluted EPS$0.57−54% from $1.24 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$46.6M−28% from $64.7M in FY 202210-K balance sheet, on EDGAR
- Cash from operations−$79.1MAgainst −$70.4M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
